Info Plexus

  Wockhardt Completes Third Phase Study Of Nafithromycin, a Macrolide Antibiotic For Pneumonia, Shares Surges The study showed a short course of three-day treatment with Nafithromycin is as effective as seven-day therapy with Moxifloxacin. Shares of Wockhardt Ltd. surged 18.80% to a near two-year high on Monday, as it successfully completed phase-3 pneumonia study of macrolide antibiotic Nafithromycin.  Nafithromycin or Wockhardt NCE, WCK 4873 was comparatively evaluated in a multi-centre double blind phase-3 pneumonia study, employing the last-line respiratory antibiotic Moxifloxacin, an exchange filing said. Findings from the phase 3 study align with earlier phase 2 research conducted in the US and Europe.  A human lung penetration study revealed that Nafithromycin maintains significantly high lung concentrations for up to five days after just three days of dosing.  Moreover, it displayed eight times higher lung exposure than Azithromycin and exhibited increased po...

The Centers for Disease Control and Prevention (CDC) has recently proposed a breakthrough solution to combat the rising rates of sexually transmitted infections (STIs). In a pioneering move, the CDC suggests the development of a new type of morning after pill that not only prevents unintended pregnancies but also provides protection against common STIs. This revolutionary approach to reproductive healthcare has the potential to significantly reduce the transmission of infections and empower individuals to take control of their sexual health. In this article, we will explore the CDC's proposal for the new morning after pill and its potential impact on preventive healthcare. Understanding the Proposal: The CDC's proposal revolves around the development of an innovative morning after pill that combines the proven contraceptive effects with additional protection against STIs. This new pill aims to create a comprehensive preventive healthcare solution, providing individuals with an ...